Instead, this study emphasized the potential importance of chemokines as biomarkers, and specifically it identifies the potential utility of CCL24 and CCR6 transcripts as novel biomarkers differentiating MDD patients from control subjects and BPD patients. The gene discussed is CCR6; the disease is major depressive disorder.